Profile data is unavailable for this security.
About the company
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
- Revenue in DKK (TTM)17.67bn
- Net income in DKK1.58bn
- Incorporated1950
- Employees5.63k
- LocationH Lundbeck A/SOttiliavej 9VALBY 2500DenmarkDNK
- Phone+45 36301311
- Fax+45 36301940
- Websitehttps://www.lundbeck.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bavarian Nordic A/S | 1.91bn | 606.31m | 13.34bn | 649.00 | 16.11 | 2.53 | 15.02 | 6.97 | 14.17 | 14.17 | 41.46 | 90.12 | 0.3186 | 4.60 | 20.94 | 5,906,361.00 | 10.09 | -2.82 | 12.11 | -3.61 | 47.60 | 66.79 | 31.68 | -9.59 | 1.54 | 45.19 | 0.4102 | -- | 32.33 | -11.45 | 4.19 | -- | 27.95 | -- |
| Recipharm AB (publ) | 8.17bn | 250.10m | 13.69bn | 7.38k | 67.03 | 3.20 | 12.77 | 1.68 | 3.47 | 3.47 | 122.51 | 72.74 | 0.6254 | 3.37 | 6.79 | -- | 1.91 | 1.42 | 2.22 | 1.63 | 48.38 | 48.03 | 3.06 | 2.52 | 1.21 | 3.77 | 0.5819 | -- | 48.43 | 26.71 | -1.25 | 9.51 | 8.56 | -- |
| AddLife AB | 3.89bn | 381.75m | 13.87bn | 988.00 | 37.10 | 10.18 | 23.66 | 3.56 | 4.61 | 4.61 | 47.03 | 16.80 | 1.42 | 6.33 | 7.56 | -- | 14.01 | -- | 24.45 | -- | 34.48 | -- | 9.86 | -- | 0.6031 | 51.69 | 0.299 | -- | 51.55 | -- | 268.42 | -- | -- | -- |
| Vaccibody AS | 63.44k | -118.21m | 16.88bn | 36.00 | -- | 152.42 | -- | 266,126.80 | -2.29 | -2.29 | 0.0008 | 0.5334 | 0.0004 | -- | 0.0084 | 3,625.00 | -67.04 | -27.40 | -72.25 | -29.59 | -- | -- | -186,331.00 | -16,364.47 | -- | -- | 0.00 | -- | 279.57 | -- | -50.42 | -- | -- | -- |
| ALK-Abello A/S | 3.49bn | 25.00m | 26.60bn | 2.45k | 1,161.87 | 9.10 | 99.24 | 7.62 | 2.26 | 2.26 | 316.19 | 288.52 | 0.6314 | 1.36 | 7.34 | 1,426,645.00 | 0.4522 | -0.3317 | 0.5498 | -0.3968 | 58.09 | 58.94 | 0.7161 | -0.5322 | 1.21 | 3.06 | 0.2302 | -- | 6.63 | 6.33 | 150.00 | -40.81 | 2.21 | -- |
| Swedish Orphan Biovitrum AB (publ) | 11.27bn | 2.40bn | 31.33bn | 1.47k | 12.80 | 2.04 | 8.06 | 2.78 | 10.91 | 10.91 | 51.29 | 68.52 | 0.3249 | 1.34 | 4.07 | -- | 6.91 | 9.75 | 8.35 | 12.22 | 78.86 | 75.41 | 21.26 | 21.68 | 0.4898 | 7.37 | 0.419 | 0.00 | 7.11 | 36.44 | -1.79 | 118.66 | 92.40 | -- |
| Orion Oyj | 8.01bn | 1.63bn | 37.30bn | 3.42k | 22.41 | 6.75 | 18.16 | 4.65 | 1.57 | 1.57 | 7.68 | 5.21 | 1.00 | 1.75 | 6.09 | -- | 20.44 | 20.17 | 25.14 | 25.56 | 60.38 | 60.27 | 20.40 | 20.82 | 2.27 | 155.61 | 0.1293 | 97.08 | 2.58 | 1.20 | 9.73 | 1.10 | -1.19 | 2.90 |
| H. Lundbeck A/S | 17.67bn | 1.58bn | 48.29bn | 5.63k | 30.49 | 2.84 | 14.98 | 2.73 | 7.95 | 7.95 | 88.90 | 85.42 | 0.4766 | 1.91 | 4.51 | 3,140,014.00 | 4.26 | 8.97 | 5.87 | 13.10 | 76.43 | 77.33 | 8.95 | 13.58 | 0.7933 | -- | 0.3173 | 49.66 | 3.73 | 3.90 | -31.65 | -- | -30.54 | -- |
Data as of Feb 25 2021. Currency figures normalised to H Lundbeck A/S's reporting currency: Danish Krone DKK
6.10%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Norges Bank Investment Managementas of 31 Dec 2019 | 2.49m | 1.25% |
| Invesco Advisers, Inc.as of 30 Sep 2020 | 2.00m | 1.00% |
| The Vanguard Group, Inc.as of 31 Jan 2021 | 1.64m | 0.82% |
| BlackRock Fund Advisorsas of 04 Feb 2021 | 1.54m | 0.78% |
| BlackRock Advisors (UK) Ltd.as of 17 Feb 2021 | 905.91k | 0.46% |
| Dimensional Fund Advisors LPas of 04 Feb 2021 | 840.94k | 0.42% |
| Handelsbanken Fonder ABas of 31 Jan 2021 | 801.12k | 0.40% |
| Nordea Investment Management AB (Denmark)as of 30 Nov 2020 | 733.04k | 0.37% |
| UBS Asset Management Switzerland AGas of 02 Feb 2021 | 620.44k | 0.31% |
| Danske Bank A/S (Investment Management)as of 19 Feb 2021 | 571.12k | 0.29% |
More ▼
Data from 31 Dec 2019 - 19 Feb 2021Source: FactSet Research Systems Inc.
